{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:50:39Z","timestamp":1794012639382,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,18]],"date-time":"2027-02-18T00:00:00Z","timestamp":1802908800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.urolonc.2025.12.004","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T20:21:53Z","timestamp":1766866913000},"page":"110968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive prostate cancer"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7138-3579","authenticated-orcid":false,"given":"Tsuyoshi","family":"Morita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7555-6295","authenticated-orcid":false,"given":"Yutaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saizo","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Maenosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tsujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Morinaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Komura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.urolonc.2025.12.004_bib0001","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with Enzalutamide or Placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.004_bib0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2025.12.004_bib0003","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"ENZAMET trial investigators and the Australian and New Zealand urogenital and Prostate cancer trials group. Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2025.12.004_bib0004","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2025.12.004_bib0005","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"10336","key":"10.1016\/j.urolonc.2025.12.004_bib0006","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.urolonc.2025.12.004_bib0007","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.urolonc.2025.12.004_bib0008","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and Docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.004_bib0009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10147-024-02649-2","article-title":"Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium","volume":"30","author":"Uchimoto","year":"2025","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.12.004_bib0010","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00345-022-04134-9","article-title":"Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer","volume":"41","author":"Matsumura","year":"2023","journal-title":"World J Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2025.12.004_bib0011","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1007\/s10147-024-02637-6","article-title":"Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor","volume":"29","author":"Yamamoto","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.12.004_bib0012","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/pros.24855","article-title":"Screening for predictive factors of efficacy of second-generation androgen receptor axis-targeted agents in patients with high-risk metastatic hormone-sensitive prostate cancer","volume":"85","author":"Ueda","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2025.12.004_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.769068","article-title":"Comparison of Abiraterone and Combined Androgen blockade therapy for high-risk metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis","volume":"11","author":"Matsumura","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.12.004_bib0014","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.12.004_bib0015","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.12.004_bib0016","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/bju.16449","article-title":"Targeted investigational treatment analysis of novel anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy","volume":"134","author":"Merseburger","year":"2024","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.urolonc.2025.12.004_bib0017","doi-asserted-by":"crossref","first-page":"253.e1","DOI":"10.1016\/j.urolonc.2023.03.003","article-title":"Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: a comparison of patients initiated on apalutamide or enzalutamide","volume":"41","author":"Lowentritt","year":"2023","journal-title":"Urol Oncol"},{"issue":"13","key":"10.1016\/j.urolonc.2025.12.004_bib0018","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/pros.24754","article-title":"Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patients","volume":"84","author":"Wenzel","year":"2024","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.urolonc.2025.12.004_bib0019","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.euo.2024.08.007","article-title":"Prostate-specific antigen nadir and cancer-control outcomes in real-world apalutamide-treated metastatic hormone-sensitive Prostate cancer patients: a single-center analysis","volume":"8","author":"Wenzel","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.12.004_bib0020","doi-asserted-by":"crossref","first-page":"271.e9","DOI":"10.1016\/j.urolonc.2024.09.028","article-title":"Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: a multicenter study","volume":"43","author":"Urabe","year":"2025","journal-title":"Urol Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2025.12.004_bib0021","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/pros.24885","article-title":"PSA absolute value versus PSA response rate: which is more valuable for estimating survival outcomes with ARPI treatment for metastatic hormone-sensitive prostate cancer (mHSPC) in real-world analyses?","volume":"85","author":"Shimomura","year":"2025","journal-title":"Prostate"},{"issue":"11","key":"10.1016\/j.urolonc.2025.12.004_bib0022","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.004_bib0023","unstructured":"National Comprehensive Cancer Network. National comprehensive cancer network clinical practice guidelines in oncology: prostate cancer. National Comprehensive Cancer Network, Inc., Plymouth Meeting, PA, USA. https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. (accessed June 2025)"},{"issue":"4","key":"10.1016\/j.urolonc.2025.12.004_bib0024","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","volume":"86","author":"Saad","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.12.004_bib0025","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.euo.2023.11.015","article-title":"Post hoc analysis of rapid and deep prostate-specific antigen decline and patient-reported health-related quality of life in SPARTAN and TITAN patients with advanced prostate cancer","volume":"7","author":"Small","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.12.004_bib0026","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2021.11.020","article-title":"Deep prostate-specific antigen response following addition of Apalutamide to ongoing androgen deprivation therapy and long-term clinical benefit in SPARTAN","volume":"81","author":"Saad","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.12.004_bib0027","unstructured":"ClinicalTrials.gov. NCT06592924. Docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer and suboptimal PSA response (TRIPLE-SWITCH). https:\/\/clinicaltrials.gov\/study\/NCT06592924. (accessed October 2025)."},{"issue":"2","key":"10.1016\/j.urolonc.2025.12.004_bib0028","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.prnil.2015.03.003","article-title":"Docetaxel in very elderly men with metastatic castration-resistant prostate cancer","volume":"3","author":"Wong","year":"2015","journal-title":"Prostate Int"},{"issue":"5","key":"10.1016\/j.urolonc.2025.12.004_bib0029","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.clgc.2021.03.016","article-title":"Efficacy and adverse events of Docetaxel for metastatic, hormone-sensitive prostate cancer among elderly men: a post hoc analysis of the CHAARTED trial","volume":"19","author":"Li","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"14","key":"10.1016\/j.urolonc.2025.12.004_bib0030","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/pros.24406","article-title":"Does castration status affect docetaxel-related adverse events? Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer","volume":"82","author":"Yanagisawa","year":"2022","journal-title":"Prostate"},{"issue":"7","key":"10.1016\/j.urolonc.2025.12.004_bib0031","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaoncol.2015.6310","article-title":"Recent trends in PSA testing and prostate cancer incidence: a look at context","volume":"2","author":"Etzioni","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.12.004_bib0032","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/iju.13870","article-title":"Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer","volume":"26","author":"Shiota","year":"2019","journal-title":"Int J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:16:03Z","timestamp":1771431363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925004879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1078143925004879"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110968"}}